Study of A3309 in Patients With Dyslipidemia

Phase 2

Completed

• Conditions: Dyslipidemia
• Interventions: Drug: A3309; Drug: Placebo

• Registration Number: NCT01069783
• Lead Sponsor: Albireo

Brief Summary

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with dyslipidemia (high cholesterol levels).

Detailed Description

Not available

Study Timeline

• Study Start: 2010-02
• Study First Submitted: 2010-02-16
• Study First Submitted QC: 2010-02-16
• Study First Posted: 2010-02-17
• Primary Completion: 2010-09
• Study Completion: 2010-09
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-06
• Last Update Posted: 2024-03-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

• Patients meet protocol specified criteria for dyslipidemia and has successfully completed study requirements with no clinically relevant findings

Exclusion Criteria

• Medical history or medical condition that would not make the patient a good candidate for the study or would limit the patient´s capability to complete the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
A3309 low dose	A3309	-
A3309 high dose	A3309	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Change from baseline in low-density lipoprotein (LDL) cholesterol	eight weeks

Trial Locations

Locations (1)

BCRC; 🇸🇪 Linköping, Sweden